On Nov. 4, 2020, Humanigen announced positive interim Phase 3 data of lenzilumab in patients hospitalized with COVID-19. This interim analysis for sizing and powering suggested that lenzilumab had a clinically meaningful impact on patient recovery, with an estimated 37 percent more recoveries observed in the lenzilumab arm of the randomized, placebo-controlled, double-blinded study versus current standard of care (SOC).